Indaptus Therapeutics (INDP) Interest Expenses (2020 - 2026)
Indaptus Therapeutics (INDP) posted quarterly Interest Expenses of $58276.0 for Q1 2026, up 123.63% year-over-year from $26059.0 in Q1 2025, and up 142.82% quarter-over-quarter from $24000.0 in Q4 2025.
Indaptus Therapeutics (INDP) Interest Expenses (2020 - 2026) Analysis & Trends
Indaptus Therapeutics' Interest Expenses history runs 7 years deep, the most recent figure standing at $58276.0 for Q1 2026.
- In Q1 2026, Interest Expenses rose 123.63% year-over-year to $58276.0; the TTM figure through Mar 2026 stood at $910141.0 (up 795.04% YoY), while the FY2025 annual figure was $60.7 million, up 6.66% from the prior year.
- Interest Expenses for Q1 2026 stood at $58276.0, up from $24000.0 in the prior quarter.
- The five-year high for Interest Expenses was $800000.0 in Q2 2025, with the low at $3290.0 in Q3 2022.
- The 5-year median for Interest Expenses is $58276.0 (2026), against an average of $169560.0.
- The sharpest annual moves came in 2022 and 2023: Interest Expenses plunged 99.68% in 2022, then jumped 16815.59% in 2023.
- Indaptus Therapeutics' Interest Expenses stood at $24476.0 in 2022, then climbed by 2.57% to $25106.0 in 2023, then increased by 2.79% to $25806.0 in 2024, then dropped by 7.0% to $24000.0 in 2025, then surged by 142.82% to $58276.0 in 2026.
- Business Quant data shows INDP's Interest Expenses at $58276.0 in Q1 2026, $24000.0 in Q4 2025, and $8686.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 82.05 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 20.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 93.62 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -4.89 Mn |
| 10 | Indaptus Therapeutics | 157.94 Mn | 146.38 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33,438.00 |
| Jun 30, 2026 | 33,438.00 |
| Mar 31, 2026 | 58,276.00 |
| Mar 31, 2026 | 58,276.00 |
| Dec 31, 2025 | 24,000.00 |
| Dec 31, 2025 | 24,000.00 |
| Sep 30, 2025 | 8,686.00 |
| Sep 30, 2025 | 8,686.00 |
| Jun 30, 2025 | 800,000.00 |
| Jun 30, 2025 | 800,000.00 |
| Mar 31, 2025 | 26,059.00 |
| Mar 31, 2025 | 26,059.00 |
| Dec 31, 2024 | 25,806.00 |
| Dec 31, 2024 | 25,806.00 |
| Sep 30, 2024 | 112,668.00 |
| Sep 30, 2024 | 112,668.00 |
| Jun 30, 2024 | 309,618.00 |
| Jun 30, 2024 | 309,618.00 |
| Mar 31, 2024 | 417,178.00 |
| Mar 31, 2024 | 417,178.00 |